Institute of Forensic Medicine and Laboratory Medicine, Jining Medical University, Hehua Road 133#, Jining City, 272067 SD, China.
Institute of Medical Technology, Qiqihar Medical University, Jianhua District, Qiqihar City, 161006 HLJ, China.
Dis Markers. 2019 Dec 7;2019:6019637. doi: 10.1155/2019/6019637. eCollection 2019.
The eukaryotic initiation factor 3 (eIF3) is the largest and most complex translation initiation factor in mammalian cells. It consists of 13 subunits and among which several were implicated to have significant prognostic effects on multiple human cancer entities. To examine the expression profiles of subunits and determine their prognostic value in patients with lung adenocarcinoma (LUAD), the genomic data, survival data, and related clinical information were obtained from The Cancer Genome Atlas (TCGA) project for a secondary analysis. The results showed that among ten aberrantly expressed subunits in tumours compared with adjacent normal counterparts ( < 0.05), only upregulated could predict poor overall survival (OS) outcome independent of multiple clinicopathological parameters (HR = 2.043, 95% CI: 1.132-3.689, = 0.018). Chi-square analysis revealed that the highly expressed group had larger ratios of patients with advanced pathological stage (68/40 vs. 184/206, = 0.0046), residual tumour (13/4 vs. 163/176, = 0.0257), and targeted molecular therapy (85/65 vs. 138/164, = 0.0357). In silico analysis demonstrated that the altered expression of was at least regulated by both copy number alterations (CNAs) and the hypomethylation of cg14297023 site. In conclusion, high expression might serve as a valuable independent prognostic indicator of shorter OS in patients with LUAD.
真核起始因子 3（eIF3）是哺乳动物细胞中最大和最复杂的翻译起始因子。它由 13 个亚基组成，其中几个亚基被认为对多种人类癌症实体具有重要的预后影响。为了研究亚基的表达谱，并确定它们在肺腺癌（LUAD）患者中的预后价值，我们从癌症基因组图谱（TCGA）项目中获取了基因组数据、生存数据和相关的临床信息进行二次分析。结果表明，与相邻正常组织相比，肿瘤中 10 个异常表达的 亚基（<0.05）中，只有上调的 可以独立于多个临床病理参数预测总生存（OS）不良结局（HR=2.043，95%CI：1.132-3.689，=0.018）。卡方分析显示，高表达 组中晚期病理分期（68/40 比 184/206，=0.0046）、残留肿瘤（13/4 比 163/176，=0.0257）和靶向分子治疗（85/65 比 138/164，=0.0357）的患者比例更大。计算机分析表明，的表达改变至少受到拷贝数改变（CNAs）和 cg14297023 位点低甲基化的调节。总之，高表达可能是 LUAD 患者 OS 较短的一个有价值的独立预后指标。
